Evidence map›Paper›PMID 42402589›Full record

ArticleJournal of nanobiotechnology2026

In situ imaging of proximal biomolecules via Proximity Anchored Modules Assembly.

Yuting Zou, Zhangling Liu, Yunpeng Shu, Shasha Zhu, Haiping Wu, Tiantian Yang, Xiaoxue Cheng, Yuanyuan Huang, Yangli Zhang, Wenlong Ren and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuting ZouThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Zhangling LiuBiobank, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Yunpeng ShuThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Shasha ZhuThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Haiping WuThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Tiantian YangThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Xiaoxue ChengDepartment of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang University, Hangzhou, 310000, P. R. China.
Yuanyuan HuangThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Yangli ZhangThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Wenlong RenThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Yi ZhangBiobank, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Shijia DingKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, P. R. China.
Wei ChengThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China. chengwei@hospital.cqmu.edu.cn.ORCID https://orcid.org/0000-0002-1921-9761
Jia LiThe Center for Clinical Molecular Medical Detection, Engineering Research Center of Chongqing Education Commission of China for IVD Technology Innovation and Translation, Laboratory Medicine Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China. lijia20210203@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant proximal biomolecular complexes are critical disease biomarkers. The precise in situ imaging of these complexes is essential for deciphering disease pathogenesis and precision diagnostics. However, current in situ analysis technologies are often constrained by limited resolution, diffusion-mediated false positives, or the requirements for rigid conjugation between recognition and amplification moieties, which hampers versatility and multiplexing. Here, we introduce Proximity Anchored Modules Assembly (PAMA), a versatile and multiplexed imaging strategy with a "plug-and-play" architecture. By decoupling target recognition from signal amplification via programmable DNA tracks synthesized by Primer Exchange Reaction (PER), PAMA triggers a polymerase-driven extension exclusively upon dual-recognition events. This mechanism ensures precise proximity-dependent activation, showing a specific signal response to homologous and heterologous targets. We further validated PAMA as a versatile platform for detection of proximal biomarkers by visualizing HER2 receptor dimerization patterns in breast cancer cells and precise discrimination of BCR-ABL

Indexed as

Biomarkers, TumorCell Line, TumorDNAErb-b2 Receptor Tyrosine KinasesFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBiomarkers, TumorDNAERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFusion Proteins, bcr-ablIn situ imagingModular DNA assemblyMultiplexed detectionProximal biomoleculesProximity extension assay

Identifiers

PMID42402589
PMCPMC13613664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.